Quest Diagnostics (DGX) Tops Q3 EPS by 10c; updates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Quest Diagnostics (DGX) PT Raised to $210 at Leerink Partners
October 21, 2025 1:09 PM EDTLeerink Partners analyst Michael Cherny raised the price target on Quest Diagnostics (NYSE: DGX) to $210.00 (from $203.00) while maintaining a Outperform rating.
The analyst comments "DGX's 3Q results were another proof point of the near-Goldilocks environment in the lab space, with the... More
